A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

ZEN003694

PO QD

DRUG

Talazoparib

PO QD

Trial Locations (19)

1070

Institut Jules Bordet, Anderlecht

3000

UZ Leuven, Leuven

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

28050

START Madrid, Madrid

30322

Emory University Winship Cancer Institute, Atlanta

37203

Tennessee Oncology (Sarah Cannon), Nashville

66203

University of Kansas Cancer Center, Westwood

77030

MD Anderson, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

233000

The First Affiliated Hosptial of Bengbu Medical College, Bengbu

272000

Affliated Hospital of Jining Medical University, Jining

300060

Tianjing Medical University Cancer Institute & Hospital, Tianjin

410000

Hunan Cancer Hospital, Changsha

510060

Sun Yat-sen University Cancer Center, Guangzhou

510289

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

641100

The Second People's Hospital of Neijiang, Neijiang

02115

Dana Farber Cancer Institute, Boston

08035

Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Newsoara Biopharma Co., Ltd.

INDUSTRY

lead

Zenith Epigenetics

INDUSTRY